BIOCARTIS: A look ahead at Biocartis’ CMD (28th Feb.) | BUY | EUR17(
BIOCARTIS - BUY | EUR17(+45%)A look ahead at Biocartis’ CMD (28th Feb.)
Reiterate Buy ahead of CMD scheduled for 28th Feb.
Nothing major in the detailed FY18 results
Keeping-up with strong placement numbers in 2019
Strategic announcements, what should we look forward to?
Biocartis Group NV is a Belgium-based company, which specializes in the development of molecular diagnostic systems, especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.